{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T23:22:59Z","timestamp":1772234579775,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An available literature data about diagnosis and management of MS is summarized in the article. The role of chemotherapy, radiation therapy, surgery and bone marrow transplantation in the treatment is discussed. Polychemotherapy and allogeneic bone marrow transplantation were suggested to be the optimal treatment strategy of MS of the gynecological tract. The use of new targeted agents results in promising clinical data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We are presenting a rare clinical case of a MS of the uterine cervix with concomitant bone marrow involvement and describe all the peculiarities of the clinical course, diagnosis, and treatment. The patient received chemotherapy followed by allogeneic bone marrow transplantation. The pre-transplant therapy allowed us to perform allogeneic bone marrow transplantation with the deepest response possible: complete PET-negative and MRD-negative remission of the disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>MS remains a subject of discussion regarding its diagnostic and therapeutic aspects. The use of novel targeting agents can be perspective option for patient with extramedullary disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-021-01328-y","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T12:20:51Z","timestamp":1620044451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4799-9398","authenticated-orcid":false,"given":"Aleksina","family":"Shatilova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa","family":"Girshova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniil","family":"Zaytsev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Budaeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuliya","family":"Mirolyubova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darya","family":"Ryzhkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Grozov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Bogdanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Nikulina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitriy","family":"Motorin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darina","family":"Zammoeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Efremova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Ivanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Petukhov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuliya","family":"Alekseeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey","family":"Zaritskey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,1]]},"reference":[{"issue":"5","key":"1328_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.clml.2017.02.027","volume":"17","author":"L Almond","year":"2017","unstructured":"Almond L, Charalampakis M, Ford S, et al. Myeloid sarcoma: presentation, diagnosis, and treatment. Clin Lymphoma Myeloma Leuk. 2017;17(5):263\u20137. https:\/\/doi.org\/10.1016\/j.clml.2017.02.027.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1328_CR2","first-page":"167","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"S Swerdlow","year":"2017","unstructured":"Swerdlow S. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2017. p. 167\u20138."},{"issue":"11","key":"1328_CR3","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1097\/PAS.0000000000000727","volume":"40","author":"K Kawamoto","year":"2016","unstructured":"Kawamoto K, Miyoshi H, Yoshida N, et al. Clinicopathological, cytogenetic, and prognostic analysis of 131 myeloid sarcoma patients. Am J Surg Pathol. 2016;40(11):1473\u201383. https:\/\/doi.org\/10.1097\/PAS.0000000000000727.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"1328_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1309\/AJCP1ZA7HYZKAZHS","volume":"132","author":"C Campidelli","year":"2009","unstructured":"Campidelli C, Agostinelli C, Stitson R, et al. Myeloid sarcoma: extramedullary manifestation of myeloid disorders. Am J Clin Pathol. 2009;132(3):426\u201337. https:\/\/doi.org\/10.1309\/AJCP1ZA7HYZKAZHS.","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"1328_CR5","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1200\/JCO.1995.13.7.1800","volume":"13","author":"JC Byrd","year":"1995","unstructured":"Byrd JC, Edenfield WJ, Shields DJ, et al. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol. 1995;13(7):1800\u201316. https:\/\/doi.org\/10.1200\/JCO.1995.13.7.1800.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1328_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ygyno.2005.04.028","volume":"98","author":"B Pathak","year":"2005","unstructured":"Pathak B, Bruchim I, Brisson ML, et al. Granulocytic sarcoma presenting as tumors of the cervix. Gynecol Oncol. 2005;98(3):493\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2005.04.028.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1328_CR7","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.3892\/ol.2019.10652","volume":"18","author":"W Gui","year":"2019","unstructured":"Gui W, Li J, Zhang Z, et al. Primary hematological malignancy of the uterine cervix: a case report. Oncol Lett. 2019;18(3):3337\u201341. https:\/\/doi.org\/10.3892\/ol.2019.10652.","journal-title":"Oncol Lett"},{"issue":"2","key":"1328_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/sj.leu.2404491","volume":"21","author":"SA Pileri","year":"2007","unstructured":"Pileri SA, Ascani S, Cox MC, et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007;21(2):340\u201350. https:\/\/doi.org\/10.1038\/sj.leu.2404491.","journal-title":"Leukemia"},{"key":"1328_CR9","doi-asserted-by":"publisher","first-page":"3042531","DOI":"10.1155\/2016\/3042531","volume":"2016","author":"V Sharma","year":"2016","unstructured":"Sharma V, Dora T, Patel M, et al. Case report of diffuse large B cell lymphoma of uterine cervix treated at a semiurban cancer centre in North India. Case Rep Hematol. 2016;2016:3042531. https:\/\/doi.org\/10.1155\/2016\/3042531.","journal-title":"Case Rep Hematol"},{"issue":"5","key":"1328_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3413\/nukmed-0236","volume":"48","author":"P Aschoff","year":"2009","unstructured":"Aschoff P, H\u00e4ntschel M, Oks\u00fcz M, et al. Integrated FDG-PET\/CT for detection, therapy monitoring and follow-up of granulocytic sarcoma. Initial Results Nuklearmedizin. 2009;48(5):185\u201391. https:\/\/doi.org\/10.3413\/nukmed-0236.","journal-title":"Initial Results Nuklearmedizin"},{"issue":"5","key":"1328_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/2040620711410774","volume":"2","author":"B Avni","year":"2011","unstructured":"Avni B, Koren-Michowitz M. Myeloid sarcoma: current approach and therapeutic options. Ther Adv Hematol. 2011;2(5):309\u201316. https:\/\/doi.org\/10.1177\/2040620711410774.","journal-title":"Ther Adv Hematol"},{"key":"1328_CR12","doi-asserted-by":"publisher","first-page":"957490","DOI":"10.1155\/2015\/957490","volume":"2015","author":"G Modi","year":"2015","unstructured":"Modi G, Madabhavi I, Panchal H, et al. Primary vaginal myeloid sarcoma: a rare case report and review of the literature. Case Rep Obstet Gynecol. 2015;2015:957490. https:\/\/doi.org\/10.1155\/2015\/957490.","journal-title":"Case Rep Obstet Gynecol"},{"key":"1328_CR13","doi-asserted-by":"publisher","unstructured":"Otoukesh S, Zhang J, Nakamura R, et al. The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement [published online ahead of print, 2020 Mar 19]. Leuk Lymphoma. 2020;1\u20134. https:\/\/doi.org\/10.1080\/10428194.2020.1742908","DOI":"10.1080\/10428194.2020.1742908"},{"issue":"7","key":"1328_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1200\/JOP.18.00753","volume":"15","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Vos J, Chargualaf MJ. Venetoclax for refractory myeloid sarcoma. J Oncol Pract. 2019;15(7):413\u20135. https:\/\/doi.org\/10.1200\/JOP.18.00753.","journal-title":"J Oncol Pract"},{"issue":"14","key":"1328_CR15","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1182\/blood-2011-04-347229","volume":"118","author":"RL Bakst","year":"2011","unstructured":"Bakst RL, Tallman MS, Douer D, et al. How I treat extramedullary acute myeloid leukemia. Blood. 2011;118(14):3785\u201393. https:\/\/doi.org\/10.1182\/blood-2011-04-347229.","journal-title":"Blood"},{"issue":"2","key":"1328_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/moh.0000000000000571","volume":"27","author":"O Shahin","year":"2020","unstructured":"Shahin O, Ravandi F. Myeloid sarcoma. Curr Opin Hematol. 2020;27(2):88\u201394. https:\/\/doi.org\/10.1097\/moh.0000000000000571.","journal-title":"Curr Opin Hematol"},{"issue":"9","key":"1328_CR17","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3324\/haematol.2011.041418","volume":"96","author":"P Chevallier","year":"2011","unstructured":"Chevallier P, Labopin M, Cornelissen J, et al. Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. Haematologica. 2011;96(9):1391\u20134. https:\/\/doi.org\/10.3324\/haematol.2011.041418.","journal-title":"Haematologica"},{"issue":"6","key":"1328_CR18","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1080\/10428194.2020.1719099","volume":"61","author":"C Lachowiez","year":"2020","unstructured":"Lachowiez C, DiNardo CD, Konopleva M. Venetoclax in acute myeloid leukemia\u2014current and future directions. Leuk Lymphoma. 2020;61(6):1313\u201322. https:\/\/doi.org\/10.1080\/10428194.2020.1719099.","journal-title":"Leuk Lymphoma"},{"key":"1328_CR19","unstructured":"Pollyea DA, Bixby D, Perl A, et al. NCCN guidelines insights: acute myeloid leukemia, version 2.2021: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw 2021;19(1):14, 45, 64."},{"key":"1328_CR20","doi-asserted-by":"publisher","first-page":"103170","DOI":"10.1016\/j.critrevonc.2020.103170","volume":"157","author":"I Cunningham","year":"2021","unstructured":"Cunningham I. Post-transplant leukemia relapse in organs: biology and behavior in 585 reports. Crit Rev Oncol\/Hematol. 2021;157:103170. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103170.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"1328_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100773","author":"RM Shallis","year":"2020","unstructured":"Shallis RM, Gale RP, Lazarus HM, et al. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: a tale of misnomers, controversy and the unresolved. Blood Rev. 2020. https:\/\/doi.org\/10.1016\/j.blre.2020.100773.","journal-title":"Blood Rev"},{"issue":"6","key":"1328_CR22","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/1097-0142(19810915)48:6<1426::aid-cncr2820480626>3.0.co;2-g","volume":"48","author":"RS Neiman","year":"1981","unstructured":"Neiman RS, Barcos M, Berard C, et al. Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer. 1981;48(6):1426\u201337. https:\/\/doi.org\/10.1002\/1097-0142(19810915)48:6%3c1426::aid-cncr2820480626%3e3.0.co;2-g.","journal-title":"Cancer"},{"issue":"2","key":"1328_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/10428194.2017.1339879","volume":"59","author":"K Kashofer","year":"2018","unstructured":"Kashofer K, Gornicec M, Lind K, et al. Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing. Leuk Lymphoma. 2018;59(2):501\u20134. https:\/\/doi.org\/10.1080\/10428194.2017.1339879.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1328_CR24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"issue":"12","key":"1328_CR25","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1080\/10428190600967196","volume":"47","author":"S Paydas","year":"2006","unstructured":"Paydas S, Zorludemir S, Ergin M. Granulocytic sarcoma: 32 cases and review of the literature. Leuk Lymphoma. 2006;47(12):2527\u201341. https:\/\/doi.org\/10.1080\/10428190600967196.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1328_CR26","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1200\/JCO.1997.15.2.466","volume":"15","author":"JC Byrd","year":"1997","unstructured":"Byrd JC, Weiss RB, Arthur DC, et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol. 1997;15(2):466\u201375. https:\/\/doi.org\/10.1200\/JCO.1997.15.2.466.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1328_CR27","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1200\/JCO.2010.29.2771","volume":"28","author":"S Lugthart","year":"2010","unstructured":"Lugthart S, Gr\u00f6schel S, Beverloo HB, et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)\/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol. 2010;28(24):3890\u20138. https:\/\/doi.org\/10.1200\/JCO.2010.29.2771.","journal-title":"J Clin Oncol"},{"key":"1328_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ajh.22256","volume":"87","author":"I Cunningham","year":"2012","unstructured":"Cunningham I. A basis for updating our approach to resistant acute leukemia. Am J Hematol. 2012;87:251\u20137. https:\/\/doi.org\/10.1002\/ajh.22256.","journal-title":"Am J Hematol"},{"key":"1328_CR29","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1002\/ajh.25594","volume":"94","author":"I Cunningham","year":"2019","unstructured":"Cunningham I, Hamele-Bena D, Guo Y, et al. Extramedullary leukemia behaving as solid cancer: clinical, histologic, and genetic clues to chemoresistance in organ sites. Am J Hematol. 2019;94:1200\u20137. https:\/\/doi.org\/10.1002\/ajh.25594.","journal-title":"Am J Hematol"},{"issue":"2","key":"1328_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/ejh.13417","volume":"105","author":"M Sitges","year":"2020","unstructured":"Sitges M, Boluda B, Garrido A, et al. Acute myeloid leukemia with inv(3)(q21.3q26.2)\/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols. Eur J Haematol. 2020;105(2):138\u201347. https:\/\/doi.org\/10.1111\/ejh.13417.","journal-title":"Eur J Haematol."},{"issue":"4","key":"1328_CR31","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.path.2013.08.007","volume":"6","author":"HJ Rogers","year":"2013","unstructured":"Rogers HJ, Hsi ED. Myeloid Neoplasms with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Surg Pathol Clin. 2013;6(4):677\u201392. https:\/\/doi.org\/10.1016\/j.path.2013.08.007.","journal-title":"Surg Pathol Clin"},{"issue":"9","key":"1328_CR32","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1080\/1042819042000219485","volume":"45","author":"PP Piccaluga","year":"2004","unstructured":"Piccaluga PP, Martinelli G, Rondoni M, et al. Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leuk Lymphoma. 2004;45(9):1791\u20135. https:\/\/doi.org\/10.1080\/1042819042000219485.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1328_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/biology9020028","volume":"9","author":"D Zaytsev","year":"2020","unstructured":"Zaytsev D, Girshova L, Ivanov V, et al. Rapid efficacy of Gemtuzumab Ozogamicin in refractory AML patients with pulmonary and kidney failure. Biology (Basel). 2020;9(2):28. https:\/\/doi.org\/10.3390\/biology9020028.","journal-title":"Biology (Basel)"},{"issue":"2","key":"1328_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000338217","volume":"128","author":"TC Tang","year":"2012","unstructured":"Tang TC, Chang H, Chuang WY. Complete response of myeloid sarcoma with FIP1L1-PDGFRA-associated myeloproliferative neoplasms to imatinib mesylate monotherapy. Acta Haematol. 2012;128(2):83\u20137. https:\/\/doi.org\/10.1159\/000338217.","journal-title":"Acta Haematol"},{"key":"1328_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40164-015-0026-x","volume":"4","author":"D Mandelker","year":"2015","unstructured":"Mandelker D, Dal Cin P, Jacene HA, et al. Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing. Exp Hematol Oncol. 2015;4:30. https:\/\/doi.org\/10.1186\/s40164-015-0026-x.","journal-title":"Exp Hematol Oncol"},{"issue":"Supplement 1","key":"1328_CR36","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.1182\/blood.V130.Suppl_1.5061.5061","volume":"130","author":"G Grillo","year":"2017","unstructured":"Grillo G, Zucchetti E, Forno B, Lotesoriere I, Inzoli E, Cairoli R. Targeted therapy in FLT3-ITD positive myeloid sarcoma: proof of principle. Blood. 2017;130(Supplement 1):5061. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.5061.5061.","journal-title":"Blood"},{"issue":"24","key":"1328_CR37","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","volume":"3","author":"DA Pollyea","year":"2019","unstructured":"Pollyea DA, Amaya M, Strati P, et al. Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019;3(24):4326\u201335. https:\/\/doi.org\/10.1182\/bloodadvances.2019000937.","journal-title":"Blood Adv"},{"issue":"10","key":"1328_CR38","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","volume":"132","author":"M Konopleva","year":"2018","unstructured":"Konopleva M, Letai A. BCL-2 inhibition in AML: an unexpected bonus? Blood. 2018;132(10):1007\u201312. https:\/\/doi.org\/10.1182\/blood-2018-03-828269.","journal-title":"Blood"},{"issue":"9","key":"1328_CR39","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.prp.2016.06.014","volume":"212","author":"HQ Wang","year":"2016","unstructured":"Wang HQ, Li J. Clinicopathological features of myeloid sarcoma: Report of 39 cases and literature review. Pathol Res Pract. 2016;212(9):817\u201324. https:\/\/doi.org\/10.1016\/j.prp.2016.06.014.","journal-title":"Pathol Res Pract"},{"key":"1328_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/4189275","volume":"2019","author":"RM Kahn","year":"2019","unstructured":"Kahn RM, Gordhandas S, Chapman-Davis E, et al. Acute myeloid leukemia presenting as myeloid sarcoma with a predisposition to the gynecologic tract. Case Rep Oncol Med. 2019;2019:1\u20135. https:\/\/doi.org\/10.1155\/2019\/4189275.","journal-title":"Case Rep Oncol Med"},{"issue":"11","key":"1328_CR41","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1080\/1042819021000016096","volume":"43","author":"J-A Hernandez","year":"2002","unstructured":"Hernandez J-A, Navarro J-T, Rozman M, et al. Primary myeloid sarcoma of the gynecologic tract: a report of two cases progressing to acute myeloid leukemia. Leuk Lymphoma. 2002;43(11):2151\u20133. https:\/\/doi.org\/10.1080\/1042819021000016096.","journal-title":"Leuk Lymphoma"},{"key":"1328_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/501342","volume":"2014","author":"M Ucar","year":"2014","unstructured":"Ucar M, Guryildirim M. Granulocytic sarcoma of the uterus: a rare presentation of extramedullary relapse of AML and importance of MRI. Case Rep Radiol. 2014;2014:1\u20134. https:\/\/doi.org\/10.1155\/2014\/501342.","journal-title":"Case Rep Radiol"},{"issue":"5","key":"1328_CR43","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1309\/H9MM-21FP-T7YB-L3PW","volume":"125","author":"MG Garcia","year":"2006","unstructured":"Garcia MG, Deavers MT, Knoblock RJ, et al. Myeloid sarcoma involving the gynecologic tract: a report of 11 cases and review of the literature. Am J Clin Pathol. 2006;125(5):783\u201390. https:\/\/doi.org\/10.1309\/H9MM-21FP-T7YB-L3PW.","journal-title":"Am J Clin Pathol"},{"key":"1328_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/812424","volume":"2010","author":"SCH Kim","year":"2010","unstructured":"Kim SCH, Natarajan-Ame S, Lioure B, et al. Successful treatment of a granulocytic sarcoma of the uterine cervix in complete remission at six-year follow-up. J Oncol. 2010;2010:1\u20133. https:\/\/doi.org\/10.1155\/2010\/812424.","journal-title":"J Oncol"},{"issue":"5","key":"1328_CR45","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00404-012-2454-8","volume":"286","author":"H Gill","year":"2012","unstructured":"Gill H, Loong F, Mak V, et al. Myeloid sarcoma of the uterine cervix presenting as missed abortion. Arch Gynecol Obstet. 2012;286(5):1339\u201341. https:\/\/doi.org\/10.1007\/s00404-012-2454-8.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"1328_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000191215","volume":"2","author":"AS Weingertner","year":"2009","unstructured":"Weingertner AS, Wilt M, Atallah I, et al. Myeloid sarcoma of the uterine cervix as presentation of acute myeloid leukaemia after treatment with low-dose radioiodine for thyroid cancer: a case report and review of the literature. Case Rep Oncol. 2009;2(1):1\u20136. https:\/\/doi.org\/10.1159\/000191215.","journal-title":"Case Rep Oncol"},{"key":"1328_CR47","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.2147\/OTT.S92815","volume":"8","author":"Y Yu","year":"2015","unstructured":"Yu Y, Qin X, Yan S, et al. Non-leukemic myeloid sarcoma involving the vulva, vagina, and cervix: a case report and literature review. Oncol Targets Ther. 2015;8:3707\u201313. https:\/\/doi.org\/10.2147\/OTT.S92815.","journal-title":"Oncol Targets Ther"},{"issue":"1","key":"1328_CR48","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13000-019-0804-6","volume":"14","author":"H Bao","year":"2019","unstructured":"Bao H, Gao J, Chen YH, et al. Rare myeloid sarcoma with KMT2A (MLL)-ELL fusion presenting as a vaginal wall mass. Diagn Pathol. 2019;14(1):26. https:\/\/doi.org\/10.1186\/s13000-019-0804-6.","journal-title":"Diagn Pathol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-021-01328-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-021-01328-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-021-01328-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T05:03:49Z","timestamp":1626843829000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-021-01328-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1328"],"URL":"https:\/\/doi.org\/10.1186\/s12905-021-01328-y","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]},"assertion":[{"value":"16 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}